Table 2.
Stage (treatment) | HR (95% CI) | p Value |
---|---|---|
Ta: | 0.04 | |
BCG | Referent | |
BCG + ACE-I/ARB | 0.45 (0.21–0.98) | |
T1: | 0.19 | |
BCG | Referent | |
BCG + ACE-I/ARB | 0.53 (0.21–1.39) | |
CIS: | 0.82 | |
BCG | Referent | |
BCG + ACE-I/ARB | 1.19 (0.25–5.78) |
Stage (treatment) | HR (95% CI) | p Value |
---|---|---|
Ta: | 0.04 | |
BCG | Referent | |
BCG + ACE-I/ARB | 0.45 (0.21–0.98) | |
T1: | 0.19 | |
BCG | Referent | |
BCG + ACE-I/ARB | 0.53 (0.21–1.39) | |
CIS: | 0.82 | |
BCG | Referent | |
BCG + ACE-I/ARB | 1.19 (0.25–5.78) |